drugset
drugset / Trial / NCT05798819

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

NCT05798819 ↗

Phase 3 Recruiting 424 enrolled Guangzhou Gloria Biosciences Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.

Timeline

Start
2023-04-20
Primary completion
2029-12-31
Completion
2030-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zimberelimab Monoclonal antibody — Intravenous
Comparator Bevacizumab Monoclonal antibody — Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Paclitaxel Small molecule — Intravenous

Indications

No indication recorded.